Trial Profile
A Two-arm, Phase 1b/2 Study of Duvelisib Administered in Combination With Rituximab or Obinutuzumab in Subjects With Previously Untreated CD20+ Follicular Lymphoma
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 03 Oct 2023
Price :
$35
*
At a glance
- Drugs Duvelisib (Primary) ; Obinutuzumab; Rituximab
- Indications Follicular lymphoma
- Focus Adverse reactions; Therapeutic Use
- Acronyms CONTEMPO
- Sponsors Infinity Pharmaceuticals; Verastem Oncology
- 08 Aug 2018 According to a Verastem Oncology media release, data from this study were presented at the ASCO 2018 and EHA 2018.
- 04 Jun 2018 According to a Verastem Oncology media release, data from this trial will be presented at the 54th Annual Meeting of the American Society of Clinical Oncology (ASCO)
- 17 May 2018 According to a Verastem Oncology media release, data from this trial will be presented at the 23rd Congress of the European Hematology Association (EHA) (June 2018).